Core Viewpoint - The announcement by the Ministry of Finance, General Administration of Customs, and State Taxation Administration outlines the continuation of import VAT preferential policies following the implementation of the VAT Law in China, specifically for anti-cancer drugs and rare disease medications from January 1, 2026, to December 31, 2027 [1]. Group 1: Import VAT Preferential Policies - The import VAT preferential policies for anti-cancer drugs and rare disease medications will continue to be effective from January 1, 2026, to December 31, 2027 [1]. - Other import VAT preferential policies that were in effect before the VAT Law and have expiration dates after January 1, 2026, will continue to be executed according to the original regulations [1]. Group 2: Advertising and Business Promotion Expenses - The policy allows for advertising and business promotion expenses incurred by cosmetic manufacturing or sales, pharmaceutical manufacturing, and beverage manufacturing (excluding alcoholic beverages) to be deductible up to 30% of the annual sales revenue, with the excess being carried forward for deduction in subsequent tax years [7]. - This policy extension provides stability for relevant enterprises from January 1, 2026, to December 31, 2027 [7]. - For ordinary enterprises, the deductible proportion for advertising expenses is set at 15%, while for VIP-level enterprises, it is 30% [7]. Group 3: Tax Sharing among Related Enterprises - Related enterprises that sign advertising and business promotion expense sharing agreements can deduct advertising and business promotion expenses within the sales revenue limit, either in their own accounts or allocate some or all to another party as per the agreement [9]. - When calculating the deductible limit for advertising and business promotion expenses, the amounts allocated to another enterprise will not be included in the calculation for that enterprise [10]. Group 4: Compliance and Documentation - Enterprises must confirm the deduction base for advertising and business promotion expenses, which should include deemed sales revenue as specified in the implementation regulations [11]. - Relevant tax documents, including ledgers, accounting vouchers, reports, tax payment certificates, invoices, and export documents, must be retained for a period of 10 years [11].

Macro Dynamics - The State Council has issued an implementation opinion to enhance the national unified electricity market, aiming to increase the scale of cross-provincial and cross-regional power transmission and the proportion of clean energy delivery over the next 5-10 years [2] - The implementation opinion emphasizes the need to improve the electricity trading system and promote market transactions between State Grid and Southern Grid, while also encouraging more private enterprises to participate in the electricity market [2] Tax Policy - The Ministry of Finance and other departments announced that the import VAT preferential policies for anti-cancer and rare disease drugs will continue from January 1, 2026, to December 31, 2027 [3] Consumer Initiatives - The Ministry of Commerce, in collaboration with nine departments, has planned a "New Spring" special event to distribute a total of 2.05 billion yuan in consumer vouchers, subsidies, and red packets during the Spring Festival [5] Market Data - From February 1 to 8, the national retail sales of passenger cars reached 328,000 units, a year-on-year increase of 54%, while wholesale sales were 284,000 units, up 46% year-on-year [7] - The A-share market showed mixed results, with the Shanghai Composite Index up 0.09% and the ChiNext Index down 1.08% [9] - The Hong Kong stock market saw the Hang Seng Index rise by 0.31% and the Hang Seng Tech Index increase by 0.9% [11] Company Dynamics - Tianji Co., Ltd. is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure, but the company states that its operations remain normal [13] - Unigroup plans to raise no more than 5.57 billion yuan through a private placement to acquire a 6.98% stake in New H3C and for other projects [14] - NetEase reported a total revenue of 112.6 billion yuan for the year 2025, with R&D investment reaching 17.7 billion yuan, marking six consecutive years of over 10 billion yuan in R&D spending [16]